for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Biosearch SA

BIOS.MC

Latest Trade

2.16EUR

Change

-0.01(-0.23%)

Volume

87,348

Today's Range

2.16

 - 

2.17

52 Week Range

0.95

 - 

2.17

As of on the Mercado Continuo Espana ∙ Minimum 15 minute delay

Pricing

Previous Close
2.17
Open
2.17
Volume
87,348
3M AVG Volume
8.48
Today's High
2.17
Today's Low
2.16
52 Week High
2.17
52 Week Low
0.95
Shares Out (MIL)
57.19
Market Cap (MIL)
124.92
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

Kerry Iberia: Spanish Council Of Ministers Authorizes Foreign Investment Resulting From Acquisition Of Control Over Biosearch

Biosearch Q1 Net Result Turns To Loss At 59,000 Euros YoY

Spanish Competition Watchdog Authorizes Potential Acquisition Of Control Over Biosearch By Kerry Group

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Biosearch SA

Biosearch SA, formerly Puleva Biotech SA, is a Spain-based company primarily engaged in the research, development and commercialization of functional food products based on natural ingredients aimed at the consecution of health positive effects that may improve the quality of life. The Company specializes in the nutrition research, which includes patents on infant formulas; the process for extraction and purification of Omega-3 acids; biotechnology projects focused on the microbial fermentation, enzymatic transformations and purification of functional lipids, and the development of functional dairy products, healthy fats, probiotics bacteria and antioxidants, among others, which are distributed under the Eupoly-Epa and Hereditum brands.

Industry

Biotechnology & Drugs

Contact Info

C/ Camino de Purchil, 66

GRANADA, GRA

18004

Spain

+34.958.240152

http://www.biosearchlife.com

Executive Leadership

Aurelio Antuna Rodriguez

Chairman of the Board

Loreto Huertas de la Camara

Chief Financial Officer

Alejandro Jara Garcia Navas

Chief Operating Officer

Jose Maria Roset Monros

General Director

Emma Madrid Sanchez-Gomez

Director of Human Resources

Key Stats

Revenue (MM, EUR)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (EUR)

2018

0.060

2019

0.010

2020

0.030

2021(E)

0.040
Price To Earnings (TTM)
80.51
Price To Sales (TTM)
4.83
Price To Book (MRQ)
4.92
Price To Cash Flow (TTM)
41.57
Total Debt To Equity (MRQ)
1.26
LT Debt To Equity (MRQ)
0.38
Return on Investment (TTM)
5.29
Return on Equity (TTM)
4.53

Latest News

Latest News

BRIEF-Biosearch Requests New International Patent For The Treatment Of Female Infertility

* REQUESTS NEW INTERNATIONAL PATENT FOR THE TREATMENT OF FEMALE INFERTILITY Source text for Eikon: Further company coverage: (Gdansk Newsroom)

BRIEF-Biosearch Q1 Net Profit Down 73% YoY, Production Activity Continues Its Normal Functioning

* Q1 REVENUE 6.6 MILLION EUROS VERSUS 5.6 MILLION EUROS YEAR AGO

BRIEF-Biosearch Launches Clinical Trial Of Hereditum Immunactiv K8 On Healthcare Personnel In Contact With Covid-19 Patients

* LAUNCHES CLINICAL TRIAL WITH ITS PRODUCT HEREDITUM IMMUNACTIV K8 ON HEALTHCARE PERSONNEL IN CONTACT WITH COVID-19 PATIENTS

BRIEF-Biosearch Applies For Two New International Patents

* SAYS PATENTS ARE FOR PREVENTION OF CARDIOVASCULAR DISEASE AND FOR THE TREATMENT OF VAGINAL INFECTIONS

BRIEF-Biosearch Expects Production Activity To Continue Its Normal Operation In Coming Months

* SAID ON MONDAY BIOSEARCH LIFE'S PRODUCTION ACTIVITY WAS EXPECTED TO CONTINUE ITS NORMAL OPERATION IN THE COMING MONTHS

BRIEF-Biosearch Signs Manufacturing And Supply Deal With Nestle

* SAYS IT SIGNS MANUFACTURING AND SUPPLY AGREEMENT WITH NESTLE FOR PATENTED PRODUCT "HEREDITUM LACTOBACILLUS FERMENTUM LC40®"

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up